GCM
TBPH icon

Graham Capital Management’s Theravance Biopharma TBPH Stock Holding History

Graham Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,296
Closed -$193K – 1497
2025
Q4 		$193K Sell
10,296
-5,815
-36% -$96.5K ﹤0.01% 1055
2025
Q3 		$235K Sell
16,111
-3,261
-17% -$41.2K ﹤0.01% 974
2025
Q2 		$214K Sell
19,372
-5,582
-22% -$54.3K ﹤0.01% 1108
2025
Q1 		$223K Sell
24,954
-11,410
-31% -$106K ﹤0.01% 1102
2024
Q4 		$342K Buy
36,364
+5,608
+18% +$51K 0.01% 877
2024
Q3 		$248K Buy
30,756
+2,197
+8% +$19K ﹤0.01% 852
2024
Q2 		$242K Buy
28,559
+12,206
+75% +$110K 0.01% 795
2024
Q1 		$147K Buy
+16,353
New +$152K ﹤0.01% 931
2023
Q3 		– Sell
-14,662
Closed -$152K – 1283
2023
Q2 		$152K Sell
14,662
-3,268
-18% -$36.1K ﹤0.01% 854
2023
Q1 		$195K Buy
+17,930
New +$190K 0.01% 969

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's TBPH Position: Q1 2026 in Review

Graham Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 10,296 shares — an estimated $193K sold.

Graham Capital Management first reported a position in TBPH in Q1 2023 and held it in 10 quarters. The position peaked at $342K in Q4 2024. 174 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Graham Capital Management reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 10,296 Theravance Biopharma shares in Q1 2026, an estimated $193K.
  • Graham Capital Management first reported a position in Theravance Biopharma in Q1 2023 and held it in 10 quarters.
  • Graham Capital Management's Theravance Biopharma position peaked at $342K in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.